严重联合免疫缺陷病匹配同胞供者移植后的结局:PIDTC报告
原发性免疫缺陷治疗联盟对1980至2023年间在30家北美机构接受匹配同胞供者造血细胞移植的133例严重联合免疫缺陷病患者进行回顾性分析。结果显示,无活动性感染或发育迟缓者5年总生存更优;使用GVHD预防或血清治疗者6个月T细胞重建可能性更低;数据提示典型SCID患者省略预处理和GVHD预防未对5年结局产生负面影响,但数据不足以推荐该做法以获得最佳长期结局。
要点
- 无活动性感染或发育迟缓者5年总生存优于有感染或发育迟缓者。
- 使用GVHD预防或血清治疗者6个月T细胞重建可能性更低。
- 数据不足以推荐省略预处理和GVHD预防以获得最佳长期结局。
核心结论
- 数据提示典型SCID患者省略预处理和GVHD预防未对匹配同胞供者移植后5年结局产生负面影响,但数据不足以推荐该做法以获得最佳长期结局。
研究设计与样本
- 原发性免疫缺陷治疗联盟回顾性分析1980至2023年间30家北美机构133例接受匹配同胞供者造血细胞移植的严重联合免疫缺陷病患者。
主要发现
- 移植时无活动性感染或发育迟缓者5年总生存优于有感染或发育迟缓者。
- 急性和慢性GVHD结局与GVHD预防、预处理方案、SCID类型或母体植入均无关。
- 移植时无活动性感染者慢性GVHD无事件生存优于有感染者。
- 使用GVHD预防或血清治疗者及漏溢型SCID或Omenn综合征患者6个月T细胞重建可能性更低。
- 6个月、1年及2-5年时,ADA、DCLRE1C或RAG基因型者T细胞重建可能性更低;1年及2-5年时,发生2-4级或3-4级急性GVHD对B细胞重建有负面影响;预处理未影响T或B细胞重建。
局限性
- 数据不足以推荐省略预处理和GVHD预防以获得最佳长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Primary Immune Deficiency Treatment Consortium performed a retrospective analysis of 133 patients with severe combined immunodeficiency (SCID) receiving matched sibling donor (MSD) hematopoietic cell transplantation (HCT) between 1980 and 2023 at 30 North American institutions. In this largest cohort of MSD outcomes in patients with SCID to date, we examined the impact of conditioning regimen and graft-versus-host disease (GVHD) prophylaxis on survival and immune recovery. Outcomes after MSD HCT for SCID were excellent. Patients without an active infection or failure to thrive (FTT) at the time of HCT had 5-year overall survival superior to those with infection or FTT. Acute and chronic GVHD outcomes were independent of GVHD prophylaxis, conditioning regimen, SCID type, or presence of maternal engraftment. Patients without active infection at the time of HCT had superior chronic GVHD-free event-free survival vs those with infection. T-cell reconstitution at 6 months was less likely achieved with use of GVHD prophylaxis or serotherapy, and in patients with leaky SCID or Omenn syndrome. At 6 months, 1 year, and 2-5 years, T-cell reconstitution was less likely with ADA, DCLRE1C, or RAG genotype. B-cell reconstitution at 1 year and 2-5 years was negatively affected by development of grade 2 to 4 or 3 to 4 acute GVHD. Conditioning did not affect T- or B-cell reconstitution. Our data suggest omitting conditioning and GVHD prophylaxis for patients with typical SCID did not negatively affect 5-year outcomes after MSD HCT, but the data are insufficient to recommend this approach for best long-term outcomes. This trial was registered at www.clinicaltrials.gov as #NCT01186913 and #NCT01346150.
引用
- Rayes A, Logan BR, Liu X, et al. Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC. Blood Adv. 2026. PMID: 41289158. doi:10.1182/bloodadvances.2025016812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。